New studies on bone marrow failure diseases presented at scientific symposium Oct. 18-19

September 30, 2005

The latest advances in aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH) and other bone marrow failure diseases will be presented at the Bone Marrow Failure Scientific Symposium Oct. 18-19 in Washington, DC. This is the first international meeting covering all bone marrow diseases--life-threatening conditions for which, in most cases, the cause is unknown.

New research on stem cell transplantation, immunosuppressive treatments, drug therapies and alternative approaches will be presented by the world's leading physicians on bone marrow failure diseases.

The symposium is sponsored by the National Institutes of Health, including the Office of Rare Diseases, the National Heart, Lung and Blood Institute and the National Cancer Institute; and organized by Aplastic Anemia & MDS International Foundation, Inc. (AA&MDSIF). Co-chairs are Jaroslaw Maciejewski, MD, PhD, Cleveland Clinic Foundation, Taussig Cancer Center and Neal S. Young, MD, National Heart, Lung and Blood Institute.

More information on the symposium is at AA&MDSIF's web site: http://www.aamds.org

What:
Bone Marrow Failure Scientific Symposium

Who:
--National Heart, Lung and Blood Institute
--National Cancer Institute
--Office of Rare Diseases
--Aplastic Anemia & MDS International Foundation, Inc.


When:
Oct. 18-19, 2005

Where:
L'Enfant Plaza Hotel, 480 L'Enfant Plaza, Washington, DC
Press must register for the symposium. Accredited journalists receive complimentary registration.
To register contact: Brian Ruberry, 301-948-1709, br@allhealthpr.com.
-end-
Founded in 1983, the Aplastic Anemia & MDS International Foundation, Inc. is dedicated to serving as a resourcefor patient assistance, advocacy, and support. AA&MDSIF provides patients and their families with educational materials and medical information, and supporting research to find treatments and cures for aplasticanemia (AA), myelodysplastic syndromes (MDS), paroxysmal nocturnal hemogloburina (PNH) and other bone marrow failure diseases.

Aplastic Anemia & MDS International Foundation

Related Myelodysplastic Syndromes Articles from Brightsurf:

Effects of acute and chronic graft-versus-myelodysplastic syndrome on long-term outcomes following a
A research group led by Assistant Professor Takaaki Konuma in the Department of Hematology/Oncology, the Hospital of the Institute of Medical Science, the University of Tokyo (IMSUT Hospital) has demonstrated a graft-versus-tumor (GVT) effect of a previously unknown/novel allogeneic hematopoietic cell transplantation in MDS patients.

RTL1 gene a likely culprit behind temple and Kagami-Ogata syndromes
Researchers from Tokyo Medical and Dental University (TMDU) have found that Rtl1, which is a mouse ortholog of the human RTL1 gene, appears to be the major gene responsible for muscle and placental defects in models of Temple and Kagami-Ogata syndromes, which are serious genetic conditions.

Identified gene mutations impact on the severity of a type of hematologic cancer
Researchers from Josep Carreras Leukemia Research Institute participate in an international study that confirms for the first time that mutation of the two TP53 gene's copies is associated with a worse prognosis in myelodysplastic syndromes, a group of blood cancers a more frequent in elderly population.

Identified the genetic landscape of myelodysplastic/myeloproliferative neoplasms
Researchers from the MDS Group of the Josep Carreras Leukaemia Research Institute and the Munich Leukemia Laboratory map the mutations that can ease and accelerate the diagnosis of Myelodysplastic/Myeloproliferative Neoplasms rare malignancies.

Merits of revascularisation and medical treatment for chronic coronary syndromes
There are two treatment goals for patients with chronic coronary syndromes: reducing the risk of hard outcomes (i.e., death, myocardial infarction) and improving health outcomes (i.e. angina symptoms, quality of life).

New treatment target verification for myelodysplastic syndrome
A Japanese research group analyzed the pathophysiology of myelodysplastic syndrome (MDS), a blood cancer that presents often in the elderly, and found the presence of transcription factor RUNX3, thereby revealing a cancer growth function for what had been considered be a tumor suppressor.

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St.

A new facial analysis method detects genetic syndromes with high precision and specificity
Developed by Araceli Morales, Gemma Piella and Federico Sukno, members of the Department of Information and Communication Technologies, together with researchers from the University of Washington, which they present in a feature in the advanced online edition of Lecture Notes in Computer Science of Oct.

Published a clinical guide for the genomic diagnosis of Myelodysplastic Syndromes and Chronic Myelomonocytic leukaemia
A collective work between researchers from 8 research centres and hospitals in Spain, coordinated by Francesc Solé of the Josep Carreras Leukaemia Research Institute (IJC), and Esperanza Such, of the University and Polytechnic Hospital de la Fe describes the recommendations of use of the Next Generation genome Sequencing (NGS) in the diagnosis of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Pollution and noise reduction advised in ESC guidelines on chronic coronary syndromes
The detrimental impact of pollution and noise on patients with chronic coronary syndromes is highlighted for the first time in European Society of Cardiology (ESC) Guidelines published online today in European Heart Journal, and on the ESC website.

Read More: Myelodysplastic Syndromes News and Myelodysplastic Syndromes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.